Herein, we demonstrated that the combinatorial targeting of MYC transcription and PI3K activity could be a valuable therapeutic option for advanced CRC, regardless of the mutational background and/or MYC gene amplification. This evidence concerns the gene MYC and colorectal carcinoma.